Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice

Article Hematology

Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone +/- daratumumab: Results from the ANDROMEDA study

Vaishali Sanchorawala et al.

Summary: In AL amyloidosis patients, treatment with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) resulted in higher rates of organ and hematologic response compared to VCd alone. Patient-reported outcomes (PROs) showed meaningful improvements in health-related quality of life (HRQoL) for the D-VCd group, with faster and more significant improvements observed compared to the VCd group.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis

Mario Nuvolone et al.

Summary: Treating AL amyloidosis poses unique challenges due to the need to deliver anti-neoplastic therapy to a hematologic malignancy causing progressive organ deterioration, particularly in elderly patients with comorbidities. Individualized risk-adapted treatment is necessary, considering organ involvement, comorbidities, and drug safety profiles.

EXPERT OPINION ON DRUG SAFETY (2021)

Add to Collection

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Hematology